RecruitingNCT04635111

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

Studying Tenosynovial giant cell tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Daiichi Sankyo
Principal Investigator
Global Clinical Leader
Daiichi Sankyo
Intervention
TURALIO™(drug)
Enrollment
30 target
Eligibility
18 years · All sexes
Timeline
20212036

Study locations (8)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04635111 on ClinicalTrials.gov

Other trials for Tenosynovial giant cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Tenosynovial giant cell tumor

← Back to all trials